A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Recruiting · Phase 1, Phase 2 · NCT04590326
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
At a glance
- Research payments reported, 2025
- $3.0M
- U.S. investigators named
- 13
- Sites paid
- 15
- Planned or actual enrollment
- 612
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- REGN5668 (drug), Cemiplimab (drug), Ubamatamab (drug), Sarilumab (drug), Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] (drug)
- Dates
- Started 2020-12-08; completion 2028-11-08
- Results posted
- Not yet
This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without sarilumab. The main purposes of this study are to: * Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus * Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus This study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, …
From ClinicalTrials.gov, last updated 2026-09-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $3.0M in research payments for this study in 2025 (196 payments).
Products named: Libtayo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mihae Song, MD Gynecologic Oncology · Duarte, CA
- Jill Tseng, M.D. Gynecologic Oncology · Irvine, CA
- Robert M. Wenham, MD Gynecologic Oncology · Tampa, FL
- John Moroney Gynecologic Oncology · Chicago, IL
- Dario Roque, MD Gynecologic Oncology · Chicago, IL
- Sara Bouberhan, MD Hematology & Oncology · Boston, MA
- Joyce F. Liu, MD Internal Medicine · Charlestown, MA
- Ira S. Winer, MD Gynecologic Oncology · Royal Oak, MI
- Deanna G. Teoh, M.D. Gynecologic Oncology · Minneapolis, MN
- Roisin E. O'cearbhaill, MB BCH Medical Oncology · New York, NY
- John L. Hays, M.D., PH.D. Medical Oncology · Columbus, OH
- Lainie P. Martin, M.D. Medical Oncology · Philadelphia, PA
- Kalyan Banda, M.D Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan Kettering Cancer Center $780,694
- Memorial Sloan Kettering Cance $402,365
- University of Washington Medical Ctr, WA $344,090
- The University of Chicago $311,475
- Karmanos Cancer Center, MI $268,184
- Dana Farber Cancer Institute $218,334
- City of Hope National Medical Ctr $137,502
- Hospital of Univ of Pennsylvania, PA $131,863
- Dana Farber Cancer Institute Inc $99,483
- Moffitt Cancer Center $86,347
- The Ohio State University $62,297
- Northwestern University $57,345
- University of California Davis Medical Center, CA $45,256
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $30,625
- Regents of the University of Minnesota $30,150
- $3,651
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.